Status:
COMPLETED
A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma
Lead Sponsor:
Seoul National University Hospital
Conditions:
Neuroblastoma
Eligibility:
All Genders
Up to 21 years
Phase:
NA
Brief Summary
Activated T cell were manufactured through in vitro T cell expansion of autologous T cell. We designed this study to determine the feasibility and safety of Activated T-lymphocyte cell therapy for ref...
Eligibility Criteria
Inclusion
- Informed consent
- Age 21 years or younger
- Histologically confirmed neuroblastoma
- Progressive disease after standard treatment or relapsed patient
- ECOG scale (ECOG-PS) ≤2
- Expected survival at least 3 months
Exclusion
- Patients with autoimmune disease
- Patients with immunodeficiency
- Other malignancy 5 year prior to this study
- Severe organ dysfunction
- Severe allergic disease
- Severe psychiatric disorder
- Pregnancy or lactating woman
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2018
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01802138
Start Date
February 1 2013
End Date
October 31 2018
Last Update
April 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, Chongno-gu, South Korea